In addition to the advent of molecularly targeted therapies, inhibition of immune checkpoints using anti–programmed cell death (ligand)-1 (PD-[L]1) monoclonal antibodies has revolutionized the management of patients with advanced NSCLC (1–6). Here, CD274 is linked to non-small cell lung carcinoma.